ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$9.79 USD
-0.14 (-1.41%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $9.98 +0.19 (1.94%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, ARS Pharmaceuticals, Inc. has a market cap of $981.35M, which represents its share price of $9.93 multiplied by its outstanding shares number of 98.83M. As a small-cap company, SPRY's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
SPRY 9.79 -0.14(-1.41%)
Will SPRY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Other News for SPRY
Is SPRY gaining bearish strength? 1,2,3 Retracement Bearish shows up after slipping 1.41%
Global Expansion and Strategic Advancements Drive Buy Rating for ARS Pharmaceuticals
ARS Pharmaceuticals (SPRY) Gains on Japanese Approval for Neffy Nasal Spray
ARS Pharma rises after Japan nod for neffy nasal spray for allergy
SPRY Gains Approval in Japan for Needle-Free Allergy Treatment